These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 29776556)
1. Sodium channel blocker challenge in Brugada syndrome: Role in risk stratification. Therasse D; Probst V; Gourraud JB Int J Cardiol; 2018 Aug; 264():100-101. PubMed ID: 29776556 [No Abstract] [Full Text] [Related]
2. Value of the sodium-channel blocker challenge in Brugada syndrome. Therasse D; Sacher F; Babuty D; Mabo P; Mansourati J; Kyndt F; Redon R; Schott JJ; Barc J; Probst V; Gourraud JB Int J Cardiol; 2017 Oct; 245():178-180. PubMed ID: 28784436 [TBL] [Abstract][Full Text] [Related]
3. New risk stratification on SCN5A mutation in Brugada syndrome. Li X; Shang H; Xing Y Int J Cardiol; 2018 Nov; 271():123. PubMed ID: 30223345 [No Abstract] [Full Text] [Related]
4. Response to letter from Drs. Li et al. regarding our paper in Int. J. Cardiol. 2018. Doi: 10.1016/j.ijcard.2017.09.010: SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers. Amin AS; Wilde AAM; Tan HL Int J Cardiol; 2018 Nov; 271():124. PubMed ID: 30223346 [No Abstract] [Full Text] [Related]
5. Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome. Dobbels B; De Cleen D; Ector J Europace; 2016 Oct; 18(10):1501-1506. PubMed ID: 26941343 [TBL] [Abstract][Full Text] [Related]
6. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Hong K; Brugada J; Oliva A; Berruezo-Sanchez A; Potenza D; Pollevick GD; Guerchicoff A; Matsuo K; Burashnikov E; Dumaine R; Towbin JA; Nesterenko V; Brugada P; Antzelevitch C; Brugada R Circulation; 2004 Nov; 110(19):3023-7. PubMed ID: 15520322 [TBL] [Abstract][Full Text] [Related]
7. Revisiting the sensitivity of sodium channel blocker testing in Brugada syndrome using obligate transmittance. Tadros R; Wilde AAM Int J Cardiol; 2017 Oct; 245():183-184. PubMed ID: 28709698 [No Abstract] [Full Text] [Related]
8. Drug Provocation Testing in Brugada Syndrome: A Test of Uncertain Significance. Sun AY JACC Clin Electrophysiol; 2019 Apr; 5(4):513-515. PubMed ID: 31000107 [No Abstract] [Full Text] [Related]
9. Sodium-channel blocker challenge in the familial screening of Brugada syndrome: Safety and predictors of positivity. Therasse D; Sacher F; Petit B; Babuty D; Mabo P; Martins R; Jesel L; Maury P; Pasquie JL; Mansourati J; Dupuis JM; Kyndt F; Thollet A; Guyomarch B; Barc J; Schott JJ; Le Marec H; Redon R; Probst V; Gourraud JB Heart Rhythm; 2017 Oct; 14(10):1442-1448. PubMed ID: 28666944 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome. Cheung CC; Mellor G; Deyell MW; Ensam B; Batchvarov V; Papadakis M; Roberts JD; Leather R; Sanatani S; Healey JS; Chauhan VS; Birnie DH; Champagne J; Angaran P; Klein GJ; Yee R; Simpson CS; Talajic M; Gardner M; Yeung-Lai-Wah JA; Chakrabarti S; Laksman ZW; Sharma S; Behr ER; Krahn AD JACC Clin Electrophysiol; 2019 Apr; 5(4):504-512. PubMed ID: 31000106 [TBL] [Abstract][Full Text] [Related]
11. Myotonic dystrophy type 1 mimics and exacerbates Brugada phenotype induced by Nav1.5 sodium channel loss-of-function mutation. Pambrun T; Mercier A; Chatelier A; Patri S; Schott JJ; Le Scouarnec S; Chahine M; Degand B; Bois P Heart Rhythm; 2014 Aug; 11(8):1393-400. PubMed ID: 24768612 [TBL] [Abstract][Full Text] [Related]
12. Malignant response to ajmaline challenge in SCN5A mutation carriers: experience from a large familial study. Gandjbakhch E; Fressart V; Duthoit G; Marquié C; Deharo JC; Pousset F; Hebert JL; Simon F; Himbert C; Klug D; Charron P; Hidden-Lucet F Int J Cardiol; 2014 Mar; 172(1):256-8. PubMed ID: 24476701 [No Abstract] [Full Text] [Related]